Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
04:59:32 EDT Fri 19 Apr 2024
Enter Symbol
or Name
USA
CA



Q:MRNS - MARINUS PHARMACEUTICALS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
MRNS - Q0.61.29·1.400.31.41-0.03-2.14,840.46,27010,2161.46  1.53  1.1711.26  1.11Apr 18Apr 1515 min RT 2¢

Recent Trades - Last 10 of 10216
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-15 07:00U:MRNSNews ReleaseMarinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results
2024-04-05 16:00U:MRNSNews ReleaseMarinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2024-03-27 08:41U:MRNSNews ReleaseMarinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus' Post Grant Review
2024-03-05 16:01U:MRNSNews ReleaseMarinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
2024-02-21 07:00U:MRNSNews ReleaseMarinus Pharmaceuticals to Present at Upcoming Investor Conferences
2024-02-20 07:00U:MRNSNews ReleaseMarinus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024
2024-02-16 16:00U:MRNSNews ReleaseMarinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2024-01-04 16:30U:MRNSNews ReleaseMarinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2024-01-04 07:01U:MRNSNews ReleaseMarinus Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2023 ZTALMY ‚ ® Net Product Revenue and Provides Business Update
2023-12-07 16:30U:MRNSNews ReleaseMarinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2023-11-20 16:01U:MRNSNews ReleaseMarinus Pharmaceuticals Announces Seven Presentations at AES 2023, New Publication in Epilepsia and Results From the Second Generation Formulation MAD Study
2023-11-14 16:05U:MRNSNews ReleaseMarinus Pharmaceuticals to Present at the 6th Annual Evercore ISI HealthCONx Conference
2023-11-09 16:30U:MRNSNews ReleaseMarinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2023-11-07 07:01U:MRNSNews ReleaseMarinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results
2023-11-07 07:00U:MRNSNews ReleaseMarinus Pharmaceuticals Initiates Global Access Program for ZTALMY ‚ ® (ganaxolone) Oral Suspension CV
2023-10-24 07:01U:MRNSNews ReleaseMarinus Pharmaceuticals to Provide Business Update and Report Third Quarter 2023 Financial Results on November 7, 2023
2023-10-06 16:00U:MRNSNews ReleaseMarinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2023-09-21 16:00U:MRNSNews ReleaseMarinus Pharmaceuticals to Present at the 2023 Cantor Global Healthcare Conference
2023-09-12 16:00U:MRNSNews ReleaseMarinus Pharmaceuticals Announces Speakers for Hybrid Investor & Analyst Event on Tuesday, September 19, 2023
2023-09-06 16:01U:MRNSNews ReleaseMarinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)